Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16435698 | 0.81 | HSD11B1 (0.48) | HSD11B1EPHX1EPHX2FKBP1A | |
| SCHEMBL12093461 | 0.74 | HSD11B1 (0.38) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL16435696 | 0.74 | EPHX1 (0.49) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL6894994 | 0.74 | HSD11B1 (0.47) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL20691792 | 0.73 | HSD11B1 (0.40) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL12094559 | 0.71 | HSD11B1 (0.36) | HSD11B1EPHX1EPHX2 | |
| SCHEMBL12198847 | 0.70 | HSD11B1 (0.41) | HSD11B1EPHX1EPHX2FKBP1A | |
| SCHEMBL1033337 | 0.70 | HSD11B1 (0.52) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL5350579 | 0.70 | HSD11B1 (0.52) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 | |
| SCHEMBL6670021 | 0.69 | HSD11B1 (0.50) | HSD11B1EPHX1EPHX2FKBP1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| US-6458780-B1 | IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-10-01 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | HSD11B1 127/4885EPHX1 3016/4885EPHX2 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.